Interestingly, previous studies on sensitivity of the panel of breast cancer cell lines to mTOR inhibitor, CCI-779, revealed that cells sensitive to CCI-779 were estrogen receptor positive, overexpressed ErbB2 and/or had lost the tumor suppressor gene product PTEN. This evidence concerns the gene PTEN and breast cancer.